MDT: No New Divestitures; Legacy Impacts Persist

Medtronic confirms on 2026-02-17 there are no new divestitures or exits to report. Management continues to pursue portfolio optimization but, per the company's filings, the current public disclosures do not include newly announced sales of business units or additional divestiture transactions. That stance sits alongside active corporate actions already disclosed in filings: the planned MiniMed separation (announced December 2025) remains in progress and generated a $16 million charge recorded in Q3 FY2026. Management is characterizing carve‑outs and separations as strategic portfolio optimization rather than simple asset sales, and the company continues to exclude amortization and restructuring items in certain non‑GAAP presentations to highlight underlying operations.

Medtronic's most recent nine‑month operating mix (ending Jan 23, 2026) shows a business weighted toward Cardiovascular (38.3%) and Neuroscience (28.4%), with Medical Surgical and Diabetes representing the balance. These segment contributions help explain where revenue resilience and margin pressure are likely to emerge as legacy issues play out. Legacy items disclosed in filings continue to influence results and the risk profile. The company remains exposed to product‑liability litigation tied to prior exits (including the HVAD System matters with thousands of plaintiffs across several forums). Antitrust litigation, SEC/DOJ anti‑corruption inquiries, environmental successor liabilities, EU MDR compliance costs, and substantial tax audits (including $2.0 billion of unrecognized tax benefits reported) create potential volatility in cash flow and earnings. Currency movements also affected derivative fair value (noted $1.7 billion impact tied to USD strength in Oct 2025). On the balance sheet and capital allocation front, Medtronic carried $28,691 million of debt with $913 million of interest expense in FY2025 and has an outstanding $5.0 billion share repurchase authorization. Intangible asset considerations remain material: accumulated intangible amortization of approximately $18,021 million as of Jan 23, 2026, plus FY2025 amortization and IPR&D activations noted in the filings.

Filings point to a narrow economic moat driven mainly by switching costs for implantable devices and moderate protection from patents/IPR&D (including $150 million of IPR&D added in FY2025). No cost‑advantage edge was identified in the disclosures; management highlights execution, product launches (e.g., cardiac ablation, transcatheter valves) and financed R&D arrangements as growth levers. While the company disclosed an option to acquire CathWorks (Feb 2026, up to $585 million plus contingent consideration) as part of its strategy to expand coronary diagnostics and analytics, the company has not announced divestitures or exits beyond previously disclosed actions. Investors should treat acquisition options and ongoing portfolio optimization as distinct from divestiture activity.